Drug Trial Radar · NCT06764238
Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
Last checked: Nov 19, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,800
Planned (sponsor's estimate)
Start
Jan 3, 2025
Primary completion
Dec 31, 2029
Study completion Jun 2031
Sponsor
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 1 month, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Building upon the results from the CCCG-ALL-2015, CCCG-ALL-2020 multicenter study cohort, concurrent research findings, and the latest clinical trials, the CCCG-ALL-2025 I/HR-B-ALL is thus developed to further improve the event-free survival (EFS), and overall survival (OS), and quality of life (QoL) of children with intermediate- and high- risk B-cell childhood acute lymphoblastic leukaemia (I/HR-B-ALL), while decreasing adverse reactions and transplantation rates. This trial primarily aims to explore: 1. The efficacy of two randomized Blinatumomab application scheme on I/HR-ALL as determined by MRD negatvitiy rate. 2. The efficacy of modified mini-hyperCVD + Venetoclax in I/HR-ALL cannot afford blinatumomab, in contrast to historical control as determined by MRD negatvitiy rate.
Conditions
- Acute Lymphoblastic Leukemia ALL
- Childhood Leukemia, Acute Lymphoblastic
- B Cell Acute Lymphoblastic Leukemia (B-ALL)
Interventions
Blinatumomab (Group A)Drug
For Group A I/HR-ALL patients after induction remission phase, continuous 28 days' blinatumomab followed by 3 cycles of high-dose methotrexate (HDMTX) will be applied, subsequently followed by interim continuation, late intensification, and maintenance therapy
Venetoclax (nonRand Group)Drug
For I/HR patients non eligible for blinatumomab randomization, venetoclax+ mini-hyperCVD will be applied after PVDL induction, subsequently followed by CAT as intensification, interim continuation, late intensification, and maintenance therapy
Blinatumomab (Group B)Drug
For Group B I/HR-ALL patients after induction remission phase: a two 14-day cycles of blinatumomab, alternating with three cycles of HDMTX will be applied, subsequently followed interim continuation, late intensification, and maintenance therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- To investigate if Group B[2*(14-day blinatumomab + HDMTX*2)] can result in noninferior event-free survival (EFS) compared to Group A [28-day blinatumomab + HDMTX*4Time frame: Based on the above analysis in this study the investigators will randomize 1800 patients. The analysis will start1.5 years after the last patient is randomized. The expected study duration is approximately 6.5 years.
Locations
27 sites in 2 countries. Site status is shown where the registry gives one.
Chongqing Medical University Affiliated Children's Hospital
Chongqing, China · Not yet recruiting
Children's Hospital of Fudan University
Shanghai, China · Not yet recruiting
Shanghai Children's Hospital
Shanghai, China · Not yet recruiting
Shanghai Children's Medical Cener, Shanghai Jiao Tong University School of Medicine
Shanghai, China · Not yet recruiting
Anhui Medical University Second Affiliated Hospital
Hefei, Anhui, China · Not yet recruiting
Anhui Provincial Children's Hospital
Hefei, Anhui, China · Not yet recruiting
Fujian Medical University Union Hospital
Fuzhou, Fujian, China · Not yet recruiting
Guangzhou Women and Children's Medical Center
Guangzhou, Guangdong, China · Not yet recruiting
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China · Not yet recruiting
The People's Hospital of Guangxi Zhuang Autonomous Region
Nanning, Guangxi, China · Not yet recruiting
The Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, China · Not yet recruiting
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Not yet recruiting
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Not yet recruiting
Wuhan Children's Hospital
Wuhan, Hubei, China · Not yet recruiting
Hunan Children's Hospital
Changsha, Hunan, China · Not yet recruiting
The Third Xiangya Hospital of the Central South University
Changsha, Hunan, China · Not yet recruiting
Xiangya Hospital Central South University
Changsha, Hunan, China · Not yet recruiting
Nanjing Children's Hospital Affiliated to Nanjing Medical University
Nanjing, Jiangsu, China · Not yet recruiting
Children's Hospital of Soochow University
Suzhou, Jiangsu, China · Not yet recruiting
Jiangxi Provincial Children's Hospital
Nanchang, Jiangxi, China · Not yet recruiting
Qilu Hospital of Shandong University
Jinan, Shandong, China · Not yet recruiting
Affiliated Hospital of Qingdao University
Qingdao, Shandong, China · Not yet recruiting
Xi'an Northwest Women and Children Hospital
Xi’an, Shanxi, China · Not yet recruiting
Shenzhen Children's Hospital
Shenzhen, Shenzhen, China · Not yet recruiting
West China Second University Hospital, Sichuan University
Chengdu, Sichuan, China · Not yet recruiting
Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC
Tianjin, Tianjin Municipality, China · Recruiting
Hong Kong Children's Hospital
Hong Kong, Hong Kong · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.